ScholarLens Back to search
2019•Unpublished venueRequires access

Euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: New drugs bring new problems

Venkatesan Thiruvenkatarajan, Emily Jane Meyer, Nagesh Nanjappa, Jane Currie, Roelof M.A.W. van Wijk, David R. Jesudason

Open publisher page 0 citations

Abstract

Diabetes is a chronic condition affecting approximately 1.2 million Australians (6%) and it is projected that 3.3 million Australians will have diabetes by 2031. Type 2 Diabetes (T2D) accounts for nearly 90% of all cases. The prevalence of diabetes among hospital in-patients is even greater (15-35% in Victoria), and it is estimated that 15% of all surgical patients have diabetes. Metformin is the first-line choice for the pharmacological treatment of T2D, but in time with progressive beta cell destruction and insulin resistance many patients require a second- and third-line medication.

About this research paper

What this paper is about

Diabetes is a chronic condition affecting approximately 1.2 million Australians (6%) and it is projected that 3.3 million Australians will have diabetes by 2031. Type 2 Diabetes (T2D) accounts for nearly 90% of all cases. The prevalence of diabetes among hospital in-patients is even greater (15-35% in Victoria), and it is estimated that 15% of all surgical patients have diabetes. Metformin is the first-line choice for the pharmacological treatment of T2D, but in time with progressive beta cell destruction and insulin resistance many patients require a second- and third-line medication.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Diabetes is a chronic condition affecting approximately 1.2 million Australians (6%) and it is projected that 3.3 million Australians will have diabetes by 2031. Type 2 Diabetes (T2D) accounts for nearly 90% of all cases. The prevalence of diabetes among hospital in-patients is even greater (15-35% in Victoria), and it is estimated that 15% of all surgical patients have diabetes. Metformin is the first-line choice for the pharmacological treatment of T2D, but in time with progressive beta cell destruction and insulin resistance many patients require a second- and third-line medication.

Key concepts: Diabetic ketoacidosis, Medicine, Metformin, Diabetes mellitus, Type 2 diabetes, Internal medicine, Insulin resistance, Insulin

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Euglycaemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: New drugs bring new problems — Research Paper | ScholarLens